Management

Open and complete information is a guiding principle for the cooperation of MorphoSys’s Management Board and Supervisory Board. They work closely together and make decisions for the benefit of the company. Their commitment objective is the sustainable increase in the company’s value.

Executive Committee

Dr. Jean-Paul Kress

Chief Executive Officer

Biography

Dr. Jean-Paul Kress

Chief Executive Officer

Year of Birth 1965
Nationality French
Management Board Member of MorphoSys AG since  2019
End of appointment 2022

Dr. Jean-Paul Kress joined MorphoSys in September 2019. He has a strong track record of commercial and (operational) strategic leadership in various senior management roles in North America and Europe. His focus has been on operations, corporate development and especially the commercialization of innovative products addressing unmet medical needs across diverse disease indications. Prior to joining MorphoSys, Dr. Kress served as President and Chief Executive Officer at Syntimmune, a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases, which was acquired by Alexion in November 2018. Among other assignments, he was Executive Vice President, President of International and Head of Global Therapeutic Operations at Biogen, and Senior Vice President, Head of North America at Sanofi Genzyme, where he was instrumental in launching Dupilumab, the first biologic agent approved in atopic dermatitis. Previously, he was President and Chief Executive Officer of Sanofi Pasteur MSD, and gained further experience in positions at Gilead, Abbvie and Eli Lilly. 

Dr. Kress received an M.D. degree from Faculté Necker-Enfants Malades in Paris, and graduate and post-graduate degrees in biochemistry and in molecular and cellular pharmacology from Ecole Normale Supérieure in Paris.
 

MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES

Erytech Pharma SA, Lyon, France (publicly listed Company)  Member of the Board of Directors
As of March 2020

 

Charlotte Lohmann

SVP General Counsel

Biography

Charlotte Lohmann

SVP General Counsel

Charlotte Lohmann joined MorphoSys in May 2012. She is a very experienced lawyer with more than 20 years of professional practice, having worked in both top tier international audit and law firms as well as in publicly listed biotech companies. 
She is an accomplished executive that has established solution-oriented legal departments with a focus on performance, effectiveness and making the legal department a true business partner. She has been successful in setting up and executing international projects as well as public listings on Frankfurt Stock Exchange and Nasdaq and has vast experience in advising management and supervisory boards (both as General Counsel and supervisory board member). 
Prior to joining MorphoSys she worked for Wilex AG as Sr. VP Legal Affairs & Human Resources and for KPMG as Corporate Lawyer.
Charlotte Lohmann holds a Law Degree from the University of Munich and is an accredited lawyer in Germany. 

 

Dr. Malte Peters

Chief Research and Development Officer

Biography

Dr. Malte Peters

Chief Research and Development Officer

Year of Birth 1962
Nationality German
Management Board Member of MorphoSys AG since 2017
End of appointment 2022

Dr. Peters joined MorphoSys from Sandoz International, Holzkirchen, Germany, where he was Global Head of Clinical Development of the Biopharmaceuticals Business Unit. Prior to this position, he served as Clinical Head and Site Head for Basel and East Hanover in the department of Oncology Translational Medicine at Novartis. Dr. Peters held teaching appointments in Internal Medicine and Biochemistry at the University of Mainz, Germany.

Dr. Peters received his MD degree from the Freie Universität Berlin, Germany, and was trained at the Universities of Padova, Italy and Bochum and Berlin, Germany. After scientific work at different universities he received his habilitation in Internal Medicine at the University of Mainz, Germany. Subsequently, he served as Research Scientist at the Amgen Research Institute in Toronto, Canada, as Director of Cancer Research at Merck KgaA in Darmstadt, Germany and as Medical Director at Micromet AG in Munich, Germany.

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Tango Therapeutics, Cambridge, MA, U.S. (not publicly listed company; group mandate) Member of the Board of Directors
As of March 2020

Dr. Barbara Krebs-Pohl

SVP, Head of Global BD&L and Alliance Management

Biography

Dr. Barbara Krebs-Pohl

SVP, Head of Global BD&L and Alliance Management

Dr. Barbara Krebs-Pohl is a highly regarded business development executive with an outstanding track record of accomplishment of revenues and forging successful alliances with pharma and biotechnology companies worldwide. 

Since joining MorphoSys in 1998, Dr. Krebs-Pohl has successfully led R&D teams, international alliances and negotiation teams spanning a broad variety of deal structures. She has been instrumental in program search & evaluation, portfolio strategy and a multitude of transactions, including the in-licensing of tafasitamab from Xencor, the long-term HuCAL alliance with Novartis and the co-development and co-commercialization partnership with Incyte. She is also the winner of the "Astra Zeneca Business Development Executive of the Year 2013" Award.

Prior to joining MorphoSys, Dr. Krebs-Pohl earned the opportunity to work with Nobel Prize winner Sir Greg Winter at MRC/LMB Cambridge, UK. She holds a PhD from the University of Mainz in Immunology, theoretical Physics and Biochemistry. She is a Master of Science (MSc) Chemistry from the University of Cologne and further trained at the RWTH Aachen University with focus on Medical Biology and Bacteriology.

Jens Holstein

Chief Financial Officer

Biography

Jens Holstein

Chief Financial Officer

Year of Birth 1963
Nationality German
Management Board Member of MorphoSys AG since 2011
End of appointment 2023

Jens Holstein joined MorphoSys from Fresenius Kabi AG, where he most recently served as Regional CFO for the region EME (Europe/Middle East) and as Managing Director of Fresenius Kabi Deutschland GmbH. Over the last almost 16 years at Fresenius he had held a variety of financial and general management positions. From 2006 to 2010, he was Regional Chief Financial Officer of Fresenius Kabi Asia Pacific Ltd., based in Hong Kong. Prior to this appointment, Mr. Holstein was Managing Director of Fresenius ProServe GmbH and Chief Financial Officer and Labor Director of the company's subsidiary Wittgensteiner Kliniken AG. Earlier positions within Fresenius included General Manager of hospitalia care GmbH, Commercial Manager of the Projects & Service business unit of Fresenius AG and Commercial Manager of hospitalia international GmbH. Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry, with positions in Frankfurt and London.

Mr. Holstein holds a Diploma in Business Administration from University of Münster.

MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES

No other memberships.

As of July 2020

Dr. Roland Wandeler

Chief Operating Officer

Biography

Dr. Roland Wandeler

Chief Operating Officer

Year of Birth 1972
Nationality Swiss
Management Board Member of MorphoSys AG since  2020
End of appointment 2023

Dr. Roland Wandeler joined MorphoSys in May 2020. He has more than 15 years of commercial leadership and general management experience in the pharmaceutical and biotechnology industry, with a strong track record of building and leading sizable affiliates and U.S. franchises across multiple therapeutic areas, including oncology and hematology. Prior to MorphoSys, Dr. Wandeler held positions of increasing responsibility at Amgen, Inc., including General Manager Germany in Munich and General Manager Spain & Portugal in Barcelona, before most recently serving as Corporate Vice President and General Manager of Amgen’s US Bone Health and Cardiology Business Unit in Thousand Oaks, California. Dr. Wandeler initially joined Amgen in 2006 in strategic planning for its international business. Subsequent highlights include sales and business unit leadership roles in Germany at the time of several launches across therapeutic areas. Dr. Wandeler began his career at Boston Consulting Group (BCG) in Zurich, Switzerland and Los Angeles, California, where he was a core member of BCG’s global Healthcare Practice as well as a Member of the Zurich and Los Angeles Management Teams.

Dr. Wandeler holds a M.Sc. in Chemical Engineering and a Doctorate in Technical Sciences from ETH Zurich.

MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES

No other memberships.

As of May 2020

 

Maria Castresana

SVP Global Head of Human Resources

Biography

Maria Castresana

SVP Global Head of Human Resources

Maria Castresana is a global HR Executive with extensive international experience in the pharmaceutical and chemical industry gained over more than 20 years of professional experience in Spain, Germany and the USA. 

Prior to joining MorphoSys in 2020, Maria Castresana held positions of increasing responsibility at Boehringer Ingelheim, a global pharmaceutical player that expanded in recent years into oncology and specialty.  She lately served as Global Head of Talent, Leadership & Organizational Effectiveness. Among other assignments, she was Global Business Partner for Consumer Health Care and led the carve-out and sale of the business in the frame of BI's and Sanofi's SWAP of CHC and Animal Health business, which closed on January 1st, 2017.  Furthermore, she spent several years in the USA and was instrumental in the set-up of new commercial launch teams for Oncology, Diabetes and Cardiovascular.

Previously, she also worked for Ecolab as European Compensation Manager and gained early experience at Bayer. 

Maria Castresana received a Law Degree and a Business Administration Degree from the University of Deusto in Spain and a Master in Human Resources from Rutgers University in the USA. 

Daniel Palmacci

SVP Global Head of Technical Operations

Biography

Daniel Palmacci

SVP Global Head of Technical Operations

Daniel Palmacci brings over 20 years of experience in the international pharmaceutical industry with responsibility for Manufacturing, Supply Chain and Operational Excellence, leading cross-functional teams responsible for Pharmaceutical cGMP Production of Biologics API and sterile Fill & Finish, Manufacturing Science & Technology and Launch Management of new biotech products and biosimilars.

Before joining MorphoSys he has been working in various senior roles at MSD and Novartis in Germany, Austria and Switzerland. He spent many years in the United States, where he was responsible for the construction of the new cGMP certified biopharmaceutical facility at Schering AG, Seattle. Later Daniel took over the responsibility for a biopharmaceutical manufacturing facility for BayerHealthCare in the United States. He has a wide multicultural experience through international assignments in Germany, Italy, India, Brazil and the US.

Daniel holds a master’s degree in Chemistry and Process Engineering from the University of Berlin.

Related links

Supervisory Board

The Supervisory Board oversees and advises the Management Board. The Board consists of professionally qualified members with many years of experience in the biotechnology and pharmaceutical industries.

Dr. Marc Cluzel

Chairman

Biography and additional memberships

Dr. Marc Cluzel

Chairman

Year of birth 1955
Nationality French
Place of residence Montpellier, France
Initial Appointment 2012
End of Period 2021

Professional Development

Currently

Member of the Supervisory Board of MorphoSys AG as well as member of comparable foreign supervisory board of a commercial enterprise (see below)

2011 – 2012

Executive Vice President of Product Development, HÙYÀ Bioscience International, LLC, San Diego, CA, USA

2009 - 2010

Executive Vice President of Research & Development, Sanofi-Aventis S.A., Paris, France

2007 – 2009

Senior Vice President of Science and Medical Affairs, Sanofi-Aventis S.A., Paris, France

2002 – 2011

Chairman and CEO, Sanofi-Aventis R&D France, Paris, France

1996 – 2001

Head of Project Direction, Sanofi R&D France, Paris, France

1993 – 1996

Project Director, Sanofi R&D France, Paris, France

1991 – 1993

Clinical Pharmacologist, Sanofi R&D France, Montpellier, France

Education

1983 – 1990

Ph.D. Biochemistry at University of Montpellier, France

1973 – 1985

M.D., Study of Medicine at University of Montpellier, France

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Moleac Pte. Ltd., Singapore*

Member of the Board of Directors

Griffon Pharmaceuticals Inc., Montreal Canada*

Member of the Board of Directors

*not publicly listed company; group mandate 

As of April 2020

Dr. George Golumbeski

Deputy Chairman

Biography and additional memberships

Dr. George Golumbeski

Deputy Chairman

Year of birth 1957
Nationality US-American
Place of residence Far Hills, NJ, USA
Initial Appointment 2018
End of Period 2020

 

Professional Development

Since 2018

Freelance business consultant in the life sciences and healthcare industries

2018 - 2019

President, Grail Inc., Menlo Park, CA, USA

2017 – 2018

Executive Vice President & Executive Advisor for Innovation, Celgene Corporation, Summit, NJ, USA

2009 – 2017

Executive Vice President, Business Development, Celgene Corporation, Summit, NJ, USA

2008 – 2009

Chief Executive Officer, Nabriva Therapeutics AG, Vienna, Austria

2002 – 2008

Vice President, Business Development, Licensing & Strategy, Novartis Oncology, Florham Park, NJ, USA

2001 – 2002

Vice President, R&D Business Development, Elan Biopharmaceuticals, San Diego, CA, USA

2000 – 2001

Senior Director, Licensing, EMD Pharmaceuticals, Durham, NC, USA

1997 – 2000

Vice President / Director, Corporate Development, Schwarz Pharma, Mequon, WI, USA

1996 – 1997

Director, Business Development, Pierce Chemical Company, Rockford, IL, USA

1991 – 1995

Technology Acquisition Manager / Group Leader, Research & Development / Group Leader, Diagnostics Research & Development, Promega Corporation, Madison, WI, USA

 

Education

1985

Ph.D., Genetics, University of Wisconsin-Madison, Madison, WI, USA

1986 – 1991

Postdoctoral Research, Molecular biology, University of Colorado Boulder, Boulder, CO, USA

1997

B.A., Biology, University of Virginia, Charlottesville, VA, USA

 

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Aura Biosciences Inc., Cambridge, MA, USA*

Chairman of the Board of Directors

Carrick Therapeutics Ltd., Dublin, Ireland*

Chairman of the Board of Directors

Enanta Pharmaceuticals, Inc.,
Watertown, MA, USA (publicly listed company)

Member of the Board of Directors

KSQ Therapeutics, Inc., Cambridge, MA, USA*

Member of the Board of Directors

Sage Therapeutics, Cambridge, MA, USA (publicly listed company)

Member of the Board of Directors

Shattuck Labs, Inc., Austin, TX, USA*

Member of the Board of Directors

Verseau Therapeutics, Bedford, MA, USA*

Chairman of the Board of Directors

* not publicly listed company; group mandate

As of April 2020

Wendy Johnson

Member

Biography and additional memberships

Wendy Johnson

Member

Year of birth 1952
Nationality US-American
Place of residence San Diego, CA, USA
Initial Appointment 2015
End of Period 2020

Professional Development

Currently

Chief Operating Officer, Reneo Pharmaceuticals, San Diego, CA, USA;
Managing Director, Gemini Advisors, San Diego, CA, USA

2007 – 2014

Founder, President and CEO, Aires Pharmaceuticals, Inc., San Diego,
CA, USA

2005 – 2014

Venture Partner, ProQuest Investments, San Diego, CA, USA

2001 – 2005

Senior Vice President Corporate Development, Salmedix, Inc., San Diego, CA, USA

2000 – 2001

Independent Consultant, San Diego, CA, USA

2000 – 1998

Vice President Business Development, Women First HealthCare, San Diego, CA, USA

1998 – 1994

Vice President Corporate Development & Operations, Selective Genetics, San Diego, CA, USA

1994 – 1990

Vice President Business Development & Regulatory Affairs, Cytel Corp., San Diego, CA, USA

1990 – 1988

Manager Business Development, Synbiotics Corp., San Diego, CA, USA

1988 – 1986

International Business Development & Regulatory Affairs Manager, Murex Corp., Cambridge, Great Britain

1986 – 1976

Assistant Director, US Food & Drug Administration, Center for Devices & Radiological Health, Rockville, MD, USA

Education

1986 – 1984

M.B.A., Loyola Marymount University, Los Angeles, CA, USA

1976 – 1974

M.S. Clinical Microbiology, Hahnemann University Hospital, Philadelphia, PA, USA

1974 – 1970

B.S. Microbiology, University of Maryland, College Park, MD, USA

No Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

As of April 2020

 

Krisja Vermeylen

Member

Biography and additional memberships

Krisja Vermeylen

Member

Year of birth 1962
Nationality Belgian
Place of residence Herentals, Belgium
Initial Appointment 2017
End of Period 2021

Professional Development

Currently

Self-employed business consultant in the life science and healthcare industries

2015 - 2018

Senior Vice President Corporate People & Organisation, Novo Nordisk A/S, Bagsvaerd, Denmark

2013 – 2015

Corporate Vice President and General Manager (CVP), Novo Nordisk Pharma GmbH, Mainz, Germany

2008 – 2013

Vice President (France & BeLux), Novo Nordisk SA, Paris, France

2002 – 2013

Vice President Europe West (France, Belgium, Luxembourg, Netherlands), Novo Nordisk SA, Paris, France

1998 – 2002

General Manager (BeLux & Director GHT France), Novo Nordisk SA, Brussels, Belgium

1997 – 1998

Marketing & Sales Manager Diabetes/Women Health Care/Growth Hormone/Haemophilia, Novo Nordisk SA, Brussels, Belgium

1997

Marketing Manager Diabetes/Women Health Care/Growth Hormone, Novo Nordisk SA, Brussels, Belgium

1996 – 1997

Senior Product Manager Anaesthesia and Cardiovascular, Pharmacia & Upjohn, Brussels, Belgium

1995

Product & Sales Manager Low molecular weight heparin, Pharmacia, Brussels, Belgium

1994 – 1995

Product Manager Anaesthesia and Cardiovascular, Pharmacia, Brussels, Belgium

1993 – 1994

Product Manager Anaesthesia, Pharmacia, Brussels, Belgium

1991 – 1993

Medical Representative Hospital Division Parenteral Nutrition, Kabi Pharmacia, Brussels, Belgium

1986 – 1991

Pharmacist dispenser

Education

2015 - 2017

Independent Director Program (IDP) INSEAD France

2002

Advanced Management Program (AMP) INSEAD France

1985 – 1986

Doctoral student of bromatology at the University of Antwerp (UIA), Antwerp, Belgium

1980 –  1985

Pharmacist / Master in pharmaceutical sciences at the University of Antwerp (UIA, RUCA), Antwerp, Belgium

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Spencer Stuart Belgien*

Member of the Advisory Board

*not publicly listed company; group mandate  

As of April 2020

Michael Brosnan

Member

Biography and additional memberships

Michael Brosnan

Member

Year of birth 1955
Nationality US-American
Place of residence Westford, MA, USA
Initial Appointment 2018
End of Period 2020

Professional development

Currently

Freelance business consultant in the life sciences and healthcare industries

2010 - 2019

Chief Financial Officer, Fresenius Medical Care Management AG, Bad Homburg v.d.H, Germany

2003 – 2009

Executive Vice President and Chief Financial Officer, Fresenius Medical Care North America, Waltham, MA, USA

1999 – 2003

Senior Vice President of Finance, Fresenius Medical Care North America, Waltham, MA, USA

1998

Vice President Finance and Administration, Spectra Renal Management, Waltham, MA, USA

1997

Vice President of Financial Operations, High Voltage Engineering Corporation, Wakefield, MA, USA

1994 – 1996

Senior Controller, Commercial Imaging Group, Polaroid Corporation, Cambridge, MA, USA

1978 – 1993

KPMG, Boston, MA, USA, (1988 – 1993 Audit Partner)

Education

1978

BSc, Business Administration, Accounting, Northeastern University, Boston, MA, USA

NO MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES

As of April 2020

Sharon Curran

Member

Biography and additional memberships

Sharon Curran

Member

Year of birth 1968
Nationality Irish
Place of residence Dublin, Ireland
Initial Appointment 2019
End of Period 2021

PROFESSIONAL DEVELOPMENT

Currently

Non-Executive Director in life sciences and healthcare industries

2014 – 2017

Vice President, Global Specialty Franchise & Customer Excellence, AbbVie, Chicago, IL, USA

2012 – 2014

Vice President and Senior Director, Global Marketing Specialty, Global Marketing & Commercial Operations, AbbVie, Chicago, IL, USA

2009 – 2012

Global Brand & Commercial Director, Abbott International Office, Ireland

2002 – 2008

Divisional Head, Strategy & Operations, Eli Lilly, UK & Ireland

1999 – 2002

Divisional Head, Primary Care Strategy & Operations, Eli Lilly, UK

1996 – 1999 

Group Marketing/Business Unit Manager, Eli Lilly, Dublin, Ireland

1995 - 1996

Hospital Sales Specialist, Eli Lilly, Dublin, Ireland

1993 – 1995

Hospital Sales Representative, Novo Nordisk, Dublin, Ireland

1992 – 1993

Medical Device Sales Representative, Dublin, Ireland

EDUCATION

2007 - 2008

MSc Business Administration, Trinity College Dublin, Ireland 

1989 -1992

BSc Biotechnology, Dublin City University, Ireland

1986 – 1989

Associate of Institute of Medical Laboratory Science, DIT/ Technological University, Dublin, Ireland

 

MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES

 

Circassia Pharmaceuticals plc., Oxford,

United Kingdom (publicly listed company)

Member of the Board of Directors

As of April 2020

Composition of the Supervisory Board UNTIL Termination of the 2020 Annual General Meeting

  Initial
Appointment
End of
Period
Audit
Committee
Remuneration and Nomination
Committee
Science
and Technology
Committee
Dr. Marc Cluzel 2012 2021   M  
Krisja Vermeylen 2017 2021 M C  
Wendy Johnson 2015 2020   M M
Dr. George Golumbeski 2018 2020     C
Michael Brosnan (FE) 2018 2020 C    
Sharron Curran 2019 2021 M    

FE=Independent Financial Expert     C=Chairperson     M=Member